Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Gainers
Goldman Sachs tips Pro Medicus as best EBITDA growth healthcare share
Growth Shares
Where to invest $20,000 in ASX shares this week
Growth Shares
Where I would invest $5,000 in ASX shares this month
Growth Shares
Why CSL and these ASX healthcare shares could be long-term market-beaters
Share Gainers
These were the best-performing shares on the ASX 200 in June
⏸️ ASX Shares
Why I would buy SEEK and these ASX blue chip shares in FY20
Growth Shares
Becoming an ASX millionaire in 2019 is as easy as ABC
Share Market News
Bring your portfolio to life with these quality ASX 200 healthcare shares
Share Market News
Why Goldman Sachs just put a sell rating on Fisher & Paykel shares
Record Highs
Why Coles, Nanosonics, and NIB shares just hit all-time highs
Record Highs
Why Goldman Sachs is sitting on the fence over ResMed shares
Growth Shares
Why I would invest $5,000 into these exciting ASX growth shares
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
